# 99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Therapy

> **NCT05412459** · — · COMPLETED · sponsor: **Tomsk National Research Medical Center of the Russian Academy of Sciences** · enrollment: 15 (actual)

## Conditions studied

- HER2-positive Breast Cancer
- Female

## Interventions

- **DRUG:** 99mTc-DARPinG3

## Key facts

- **NCT ID:** NCT05412459
- **Lead sponsor:** Tomsk National Research Medical Center of the Russian Academy of Sciences
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-01-31
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05412459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05412459, "99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Therapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05412459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*